Compare KALA & TCBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KALA | TCBS |
|---|---|---|
| Founded | 2009 | 1934 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.8M | 48.5M |
| IPO Year | 2017 | 2021 |
| Metric | KALA | TCBS |
|---|---|---|
| Price | $1.69 | $17.73 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $31.50 | N/A |
| AVG Volume (30 Days) | ★ 142.2K | 4.1K |
| Earning Date | 04-15-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 1.18% |
| EPS Growth | 67.39 | ★ 327.27 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $57.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $15.10 |
| 52 Week High | $20.58 | $20.00 |
| Indicator | KALA | TCBS |
|---|---|---|
| Relative Strength Index (RSI) | 38.94 | 54.65 |
| Support Level | $0.32 | $16.02 |
| Resistance Level | $1.81 | $18.26 |
| Average True Range (ATR) | 0.45 | 0.35 |
| MACD | -0.17 | 0.05 |
| Stochastic Oscillator | 3.85 | 50.98 |
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans, commercial real estate loans, and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer, and other.